Biallelic inactivation of BRCA2 in Fanconi anemia

被引:882
作者
Howlett, NG
Taniguchi, T
Olson, S
Cox, B
Waisfisz, Q
de Die-Smulders, C
Persky, N
Grompe, M
Joenje, H
Pals, G
Ikeda, H
Fox, EA
D'Andrea, AD
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat, Boston, MA 02115 USA
[3] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA
[4] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA
[5] Free Univ Amsterdam, Med Ctr, Dept Clin Genet & Human Genet, NL-1081 BT Amsterdam, Netherlands
[6] Univ Limburg, Acad Hosp Maastricht, Dept Clin Genet, Maastricht, Netherlands
[7] Sapporo Med Univ, Sch Med, Dept Pathol, Chuo Ku, Sapporo, Hokkaido 0608557, Japan
关键词
D O I
10.1126/science.1073834
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Fanconi anemia ( FA) is a rare autosomal recessive cancer susceptibility disorder characterized by cellular hypersensitivity to mitomycin C (MMC). Six FA genes have been cloned, but the gene or genes corresponding to FA subtypes B and D1 remain unidentified. Here we show that cell lines derived from FA-B and FA-D1 patients have biallelic mutations in BRCA2 and express truncated BRCA2 proteins. Functional complementation of FA-D1 fibroblasts with wild-type BRCA2 complementary DNA restores MMC resistance. Our results link the six cloned FA genes with BRCA1 and BRCA2 in a common pathway. Germ-line mutation of genes in this pathway may result in cancer risks similar to those observed in families with BRCA1 or BRCA2 mutations.
引用
收藏
页码:606 / 609
页数:5
相关论文
共 32 条
  • [1] Alter BP, 1996, AM J HEMATOL, V53, P99, DOI 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.0.CO
  • [2] 2-Z
  • [3] Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310
  • [4] STUDIES OF GENE-TRANSFER AND REVERSION TO MITOMYCIN-C RESISTANCE IN FANCONI ANEMIA CELLS
    BUCHWALD, M
    NG, J
    CLARKE, C
    DUCKWORTHRYSIECKI, G
    [J]. MUTATION RESEARCH, 1987, 184 (02): : 153 - 159
  • [5] Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells
    Chen, JJ
    Silver, DP
    Walpita, D
    Cantor, SB
    Gazdar, AF
    Tomlinson, G
    Couch, FJ
    Weber, BL
    Ashley, T
    Livingston, DM
    Scully, R
    [J]. MOLECULAR CELL, 1998, 2 (03) : 317 - 328
  • [6] Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation
    Connor, F
    Bertwistle, D
    Mee, PJ
    Ross, GM
    Swift, S
    Grigorieva, E
    Tybulewicz, VLJ
    Ashworth, A
    [J]. NATURE GENETICS, 1997, 17 (04) : 423 - 430
  • [7] CONSTRUCTION AND CHARACTERIZATION OF A HIGHLY STABLE HUMAN-RODENT MONOCHROMOSOMAL HYBRID PANEL FOR GENETIC COMPLEMENTATION AND GENOME MAPPING STUDIES
    CUTHBERT, AP
    TROTT, DA
    EKONG, RM
    JEZZARD, S
    ENGLAND, NL
    THEMIS, M
    TODD, CM
    NEWBOLD, RF
    [J]. CYTOGENETICS AND CELL GENETICS, 1995, 71 (01): : 68 - 76
  • [8] Role of BRCA2 in control of the RAD51 recombination and DNA repair protein
    Davies, AA
    Masson, JY
    Mcllwraith, MJ
    Stasiak, AZ
    Stasiak, A
    Venkitaraman, AR
    West, SC
    [J]. MOLECULAR CELL, 2001, 7 (02) : 273 - 282
  • [9] Interaction of the fanconi anemia proteins and BRCA1 in a common pathway
    Garcia-Higuera, I
    Taniguchi, T
    Ganesan, S
    Meyn, MS
    Timmers, C
    Hejna, J
    Grompe, M
    D'Andrea, AD
    [J]. MOLECULAR CELL, 2001, 7 (02) : 249 - 262
  • [10] Goggins M, 1996, CANCER RES, V56, P5360